The role of NF-k{cyrillic}B in SAA-induced peroxisome proliferator-activated receptor γ activation

Atherosclerosis

Volumn 227, Issue 1, 2013, Pages 72-78

  Li, Hongzhe ^a   Ooi, Shu Qin ^a   Heng, Chew Kiat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

FPRL 1; NF kB; PPAR ; SAA; TLR4

Indexed keywords

CYCLOOXYGENASE 2; FORMYLPEPTIDE RECEPTOR LIKE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SERUM AMYLOID A; TOLL LIKE RECEPTOR 4; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; FLAVONOID; FORMYLPEPTIDE RECEPTOR; FPR2 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN; LIPOXIN RECEPTOR; PTGS2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ARTICLE; BIOLOGICAL ACTIVITY; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

CYCLOOXYGENASE 2; FLAVONOIDS; HEP G2 CELLS; HUMANS; LIPOPROTEINS, HDL; NF-KAPPA B; PPAR GAMMA; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SERUM AMYLOID A PROTEIN; TOLL-LIKE RECEPTOR 4;

MLCS; MLOWN;

EID: 84873428825     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.12.007     Document Type: Article

References (60)

1. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999, 265:501-523.
2. Kisilevsky R., Tam S.P. Acute phase serum amyloid A, cholesterol metabolism, and cardiovascular disease. Pediatr Pathol Mol Med 2002, 21:291-305.
3. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982, 389:39-48.
4. Urieli-Shoval S., Cohen P., Eisenberg S., Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 1998, 46:1377-1384.
5. Malle E., De Beer F.C. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996, 26:427-435.
6. Clifton P.M., Mackinnon A.M., Barter P.J. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res 1985, 26:1389-1398.
7. Coetzee G.A., Strachan A.F., van der Westhuyzen D.R., Hoppe H.C., Jeenah M.S., de Beer F.C. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986, 261:9644-9651.
8. Banka C.L., Yuan T., De Beer, et al. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995, 36:1058-1065.
9. Kisilevsky R. Serum amyloid A (SAA), a protein without a function: some suggestions with reference to cholesterol metabolism. Med Hypotheses 1991, 35:337-341.
10. Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol 2001, 13:67-73.
11. Urieli-Shoval S., Linke R.P., Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000, 7:64-69.
12. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
13. Kliewer S.A., Forman B.M., Blumberg B., et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 1994, 91:7355-7359.
14. Lemberger T., Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996, 12:335-363.
15. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995, 83:813-819.
16. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
17. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803-812.
18. Kliewer S.A., Sundseth S.S., Jones S.A., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997, 94:4318-4323.
19. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93:229-240.
20. Li H., Zhao Y., Zhou S., Heng C.K. Serum amyloid A activates peroxisome proliferator-activated receptor gamma through extracellularly regulated kinase 1/2 and COX-2 expression in hepatocytes. Biochemistry 2010, 49:9508-9517.
21. Green D.R. Death and NF-kappaB in T cell activation: life at the edge. Mol Cell 2003, 11:551-552.
22. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3:221-227.
23. Perkins N.D. The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci 2000, 25:434-440.
24. Chen Z., Hagler J., Palombella V.J., et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995, 9:1586-1597.
25. Henkel T., Machleidt T., Alkalay I., Kronke M., Ben-Neriah Y., Baeuerle P.A. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 1993, 365:182-185.
26. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
27. Tanaka T., Grusby M.J., Kaisho T. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007, 8:584-591.
28. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev 2004, 18:2195-2224.
29. Chun K.S., Surh Y.J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004, 68:1089-1100.
30. Tsatsanis C., Androulidaki A., Venihaki M., Margioris A.N. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006, 38:1654-1661.
31. Rothwarf D.M., Karin M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999, 1999:RE1.
32. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004, 25:280-288.
33. Li H, Zhao Y, Zhou S, Heng CK. SAA activates peroxisome proliferator-activated receptor gamma through extracellular-regulated kinase 1/2 and COX-2 expression in hepatocytes, Biochemistry.
34. Kosaka T., Miyata A., Ihara H., et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 1994, 221:889-897.
35. D'Acquisto F., Iuvone T., Rombola L., Sautebin L., Di Rosa M., Carnuccio R. Involvement of NF-kappaB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett 1997, 418:175-178.
36. Kojima M., Morisaki T., Izuhara K., et al. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene 2000, 19:1225-1231.
37. Zhao Y., Zhou S., Heng C.K. Celecoxib inhibits serum amyloid a-induced matrix metalloproteinase-10 expression in human endothelial cells. J Vasc Res 2009, 46:64-72.
38. Klein C., Paul J.I., Sauve K., et al. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. Nat Biotechnol 1998, 16:1334-1337.
39. Baek S.H., Seo J.K., Chae C.B., Suh P.G., Ryu S.H. Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries. J Biol Chem 1996, 271:8170-8175.
40. Bae Y.S., Bae H., Kim Y., Lee T.G., Suh P.G., Ryu S.H. Identification of novel chemoattractant peptides for human leukocytes. Blood 2001, 97:2854-2862.
41. Deng X., Ueda H., Su S.B., et al. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood 1999, 94:1165-1173.
42. Bae Y.S., Lee H.Y., Jo E.J., et al. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol 2004, 173:607-614.
43. He R., Sang H., Ye R.D. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 2003, 101:1572-1581.
44. Walder K., Kantham L., McMillan J.S., et al. Tanis: a link between type 2 diabetes and inflammation?. Diabetes 2002, 51:1859-1866.
45. Cai L., de Beer M.C., de Beer F.C., van der Westhuyzen D.R. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 2005, 280:2954-2961.
46. Cai H., Song C., Endoh I., et al. Serum amyloid A induces monocyte tissue factor. J Immunol 2007, 178:1852-1860.
47. Cheng N., He R., Tian J., Ye P.P., Ye R.D. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 2008, 181:22-26.
48. Rigotti A., Miettinen H.E., Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003, 24:357-387.
49. Connelly M.A., Williams D.L. Scavenger receptor BI: a scavenger receptor with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol 2004, 15:287-295.
50. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004, 4:469-478.
51. Wang L., Colon W. The interaction between apolipoprotein serum amyloid A and high-density lipoprotein. Biochem Biophys Res Commun 2004, 317:157-161.
52. Lee H.Y., Kim M.K., Park K.S., et al. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun 2005, 330:989-998.
53. Bae Y.S., Yi H.J., Lee H.Y., et al. Differential activation of formyl peptide receptor-like 1 by peptide ligands. J Immunol 2003, 171:6807-6813.
54. Bae Y.S., Park J.C., He R., et al. Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in human neutrophils. Mol Pharmacol 2003, 64:721-730.
55. Tolle M., Huang T., Schuchardt M., et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 2012, 94:154-162.
56. Annema W., Nijstad N., Tolle M., et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J Lipid Res 2010, 51:743-754.
57. Kisilevsky R., Tam S.P., Ancsin J.B. The anti-atherogenic potential of serum amyloid A peptides. Curr Opin Investig Drugs 2008, 9:265-273.
58. Meek R.L., Urieli-Shoval S., Benditt E.P. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A 1994, 91:3186-3190.
59. Kumon Y., Suehiro T., Hashimoto K., Nakatani K., Sipe J.D. Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J Rheumatol 1999, 26:785-790.
60. Badolato R., Wang J.M., Murphy W.J., et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994, 180:203-209.